In the management of anxietyTo?sopam is as much as effective as classical benzodiazepines in the management of anxiety.
Tofisopam is found to be effective in management of alcohol withdrawal symptom with less sedative effects as compared to benzodiazepines like diazepam
50–300 mg per day divided into three doses.
Like other benzodiazepines, it possesses anxiolytic properties, but, unlike other benzodiazepines, it does not have anticonvulsant, sedative, skeletal muscle relaxant, motor skill-impairing, or amnestic properties.
In comparison with Midozolam, Tofisopam reduces preoperative anxiety of the patients but without sedative action.
Tofisopam is not reported as causing dependence to the same extent as other benzodiazepines
Discontinue if sleep disturbances occur. Avoid sleep disturbances by taking last dose earlier (e.g. before 5 pm).Contraindicated in pregnancyTofisopam is a 2,3-benzodiazepine drug which is a benzodiazepine derivative. In contrast to classical 1,4-benzodiazepines, the compound does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor and its psychopharmacological profile differs from such compounds.
Like other benzodiazepines, Tofisopam possesses anxiolytic properties but unlike other benzodiazepines it does not have anticonvulsant, sedative, skeletal muscle relaxant, and motor skill-impairing or amnestic properties. It enhances the anticonvulsant activity of 1, 4-benzodiazepines like diazepam but not sodium valproate, carbamazepine, phenobarbital, or phenytoin.
Tofisopam does not bind to the benzodiazepine binding site of the gamma-aminobutyric acid receptor. One study (Rundfeldt C. et al.) has shown that Tofisopam acts as an isoenzyme-selective inhibitor of phosphodiesterases (PDEs) with highest affinity to PDE-4A1 (0.42 ?M) followed by PDE-10A1 (0.92 ?M), PDE-3 (1.98 ?M) and PDE-2A3 (2.11 ?M).
Major & minor side effects for Tofisopam
Nausea
Stomach discomfort
Fever
Dry mouth
Skin Rash
Sleeplessness
Headache
Vomiting
Drowsiness
